Background：Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 CCL2. The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of IPF with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.
